Scandion Oncology: Edison Open House Healthcare 2022

Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy.

• Tell us what the company does and its lead asset, SCO-101?
• How does this allow you to better manage the dose in oncology treatment?
• What does the discovery of a biomarker for SCO-101 treatment in the CORIST study mean for the clinical application?
• On your website you say the market for Scandion Oncology’s products is more than €4 bn. How did you arrive at this figure?
• Do you consider that the ability of your product to allow lower dosages to be given will be attractive to payers?
• Assuming a positive result in Phase II trials for SCO-101, how do you envisage the execution of Phase III trials? How will this be funded?
• Where does Scandion’s interest in immuno-oncology fit into its development plans?
• Could you elaborate for investors on the value of your intellectual property portfolio?
• What should investors look out for in the upcoming months?